Thanks posters above for clarifying. Sounds like it could be more of a distortionary threat then.
It would be a shame for the patient if this initiative redirected investment toward less effective but higher NPAT biotechs with new patents in similar spaces. Gov might need to think it through a bit harder.
Thanks posters above for clarifying. Sounds like it could be...
-
- There are more pages in this discussion • 8,298 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.86 |
Change
-0.015(0.80%) |
Mkt cap ! $316.8M | |||
| Open | High | Low | Value | Volume |
| $1.88 | $1.88 | $1.79 | $163.0K | 89.00K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34299 | $1.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.86 | 3635 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |